

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
MAJOR RESULTS OF A DOMESTIC STUDY ON PROTECTIVE EFFICACY
OF COVID-19 VARIANT OMICRON BA.5 mRNA
VACCINE LVRNA012

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that recently, an investigator-initiated clinical study on the protective efficacy and safety of our Group’s COVID-19 variant Omicron BA.5 mRNA vaccine LVRNA012, which was carried out in China, has completed interim analysis of key data and obtained major results, with the highest protection rate reaching 80.68%.

The study aims to evaluate the protective efficacy, safety and immunogenicity of the vaccine in people aged 18 or above who receive one dose of this vaccine as booster. The vast majority of COVID-19 cases collected after 7 days of vaccination were mild in terms of symptoms, with some isolated cases being medium. The vaccine’s protection rate against diseases caused by COVID-19 infection of any severity was 73.16% with a 95% confidence interval of (54.24%, 85.00%), which was far above the international standards for protective efficacy of COVID-19 vaccines (i.e., protective efficacy rate of 50% or above with the lower limit of the 95% confidence interval at 30% or above.)

In particular, since late April 2023, with the XBB variant being the predominant strain in China (amounting to 96%, according to observation data from GISAID), the vaccine's standalone protection rate for the cases reported in this period reached 80.68% with a 95% confidence interval of (55.98%, 92.74%). The results showed that, even though the dominant strains in China changed from BA.5.2, BF.7 and their sub-variants to XBB and its sub-variants since late April 2023, the vaccine's protection rate was not reduced, and on the contrary demonstrated a higher protective efficacy. Based solely on results obtained from this study, it is observed that this vaccine offers better protection against the XBB variants.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, June 1, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.